Chemoprevention in colorectal cancer - where we stand and what we have learned from twenty year's experience

Surgeon

Volumn 10, Issue 1, 2012, Pages 43-52

  Boghossian, Shahe ^a   Hawash, Ahmed ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Adenoma; Chemoprevention; Colorectal Cancer; Non steroidal anti inflammatory; Polyps

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; METFORMIN; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; RESVERATROL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STILBENE DERIVATIVE;

COLORECTAL TUMOR; HUMAN; PATHOLOGY; PRECANCER; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTICARCINOGENIC AGENTS; COLORECTAL NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; METFORMIN; PRECANCEROUS CONDITIONS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STILBENES;

EID: 84855515509     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surge.2011.07.003     Document Type: Review

References (70)

1. Chan A., Miles D.W., Pivot X. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol 2010.
2. Ortega J., Vigil C.E., Chodkiewicz C. Current progress in targeted therapy for colorectal cancer. Cancer Control 2010, 17(1):7-15.
3. Crane C.H., Winter K., Regine W.F., Safran H., Rich T.A., Curran W., et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 2009, 27(25):4096-4102.
4. Kozloff M., Yood M.U., Berlin J., Flynn P.J., Kabbinavar F.F., Purdie D.M., et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009, 14(9):862-870.
5. Sobrero A., Ackland S., Clarke S., Perez-Carrion R., Chiara S., Gapski J., et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009, 77(2):113-119.
6. Meriggi F., Abeni C., Di Biasi B., Zaniboni A. The use of bevacizumab and trastuzumab beyond tumor progression: a new avenue in cancer treatment?. Rev Recent Clin Trials 2009, 4(3):163-167.
7. Manzoni M., Rovati B., Ronzoni M., Loupakis F., Mariucci S., Ricci V., et al. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology 2010, 79(3-4):187-196.
8. Chibaudel B., Maindrault-Goebel F., Lledo G., Mineur L., Andre T., Bennamoun M., et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009, 27(34):5727-5733.
9. Lievre A.B.J., Le Corre D., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., et al. KRAS mutation is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66(8):3992-3995.
10. Tol J., Nagtegaal I.D., Punt C.J. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009, 361(1):98-99.
11. Tol J.K.M., Cats A., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., et al. Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer. N Eng J Med 2009, 360:563-572.
12. Lin C.C., Calvo E., Papadopoulos K.P., Patnaik A., Sarantopoulos J., Mita A.C., et al. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009, 63(6):1065-1071.
13. Mathew S., George S.P., Wang Y., Siddiqui M.R., Srinivasan K., Tan L., et al. Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration. J Biol Chem 2008, 283(33):22709-22722.
14. Kopetz S. Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. Gastrointest Cancer Res 2007, 1(4 Suppl. 2):S37-S41.
15. Kline C.L., Olson T.L., Irby R.B. Src activity alters alpha3 integrin expression in colon tumor cells. Clin Exp Metastasis 2009, 26(2):77-87.
16. Trevino J.G., Summy J.M., Gallick G.E. SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem 2006, 6(6):681-687.
17. Barone M., Tanzi S., Lofano K., Scavo M.P., Guido R., Demarinis L., et al. Estrogens, phytoestrogens and colorectal neoproliferative lesions. Genes Nutr 2008, 3(1):7-13.
18. Pietras R.J. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J 2003, 9(5):361-373.
19. Weinberg O.K., Marquez-Garban D.C., Pietras R.J. New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Updat 2005, 8(4):219-233.
20. Hartman J., Edvardsson K., Lindberg K., Zhao C., Williams C., Strom A., et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 2009, 69(15):6100-6106.
21. Francesca C., Taddei A., Degl'innocenti D.R., Buccoliero A.M., Bechi P., Garbini F., et al. Expression of estrogen beta receptors in colon cancer progression. Diagn Mol Pathol 2007.
22. Motylewska E., Stasikowska O., Melen-Mucha G. The inhibitory effect of diarylpropionitrile, a selective agonist of estrogen receptor beta, on the growth of MC38 colon cancer line. Cancer Lett 2009, 276(1):68-73.
23. Weige C.C., Allred K.F., Allred C.D. Estradiol alters cell growth in nonmalignant colonocytes and reduces the formation of preneoplastic lesions in the colon. Cancer Res 2009, 69(23):9118-9124.
24. Vigushin D.M., Coombes R.C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 2002, 13(1):1-13.
25. Fahey J.W., Zhang Y., Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci U S A 1997, 94(19):10367-10372.
26. Ho E., Clarke J.D., Dashwood R.H. Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr 2009, 139(12):2393-2396.
27. Andelova H., Rudolf E., Cervinka M. Invitro antiproliferative effects of sulforaphane on human colon cancer cell line SW620. Acta Med (Hradec Kralove) 2007, 50(3):171-176.
28. Rudolf E., Andelova H., Cervinka M. Activation of several concurrent proapoptic pathways by sulforaphane in human colon cancer cells SW620. Food Chem Toxicol 2009, 47(9):2366-2373.
29. Shen G., Khor T.O., Hu R., Yu S., Nair S., Ho C.T., et al. Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse. Cancer Res 2007, 67(20):9937-9944.
30. Feinman R., Clarke K.O., Harrison L.E. Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kappaB IN HT-29 colon cancer cells. Cancer Chemother Pharmacol 2002, 49(1):27-34.
31. Sowa Y., Sakai T. Butyrate as a model for "gene-regulating chemoprevention and chemotherapy.". Biofactors 2000, 12(1-4):283-287.
32. Sung M.W., Waxman S. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res 2007, 27(2):995-1001.
33. Cho S.D., Lei P., Abdelrahim M., Yoon K., Liu S., Guo J., et al. 1,1-bis(3'-indolyl)-1-(p-methoxyphenyl)methane activates Nur77-independent proapoptotic responses in colon cancer cells. Mol Carcinog 2008, 47(4):252-263.
34. Bhatnagar N., Li X., Chen Y., Zhou X., Garrett S.H., Guo B. 3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prev Res (Phila Pa) 2009, 2(6):581-589.
35. Chintharlapalli S., Smith R., Samudio I., Zhang W., Safe S. 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor gamma-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells. Cancer Res 2004, 64(17):5994-6001.
36. Corfe B.M., Williams E.A., Bury J.P., Riley S.A., Croucher L.J., Lai D.Y., et al. A study protocol to investigate the relationship between dietary fibre intake and fermentation, colon cell turnover, global protein acetylation and early carcinogenesis: the FACT study. BMC Cancer 2009, 9:332.
37. Kimura Y., Sumiyoshi M., Baba K. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action. Cancer Sci 2008, 99(10):2083-2096.
38. Li H., Wu W.K., Zheng Z., Che C.T., Yu L., Li Z.J., et al. 2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, is a potent inducer of apoptosis in colon cancer cells via targeting microtubules. Biochem Pharmacol 2009, 78(9):1224-1232.
39. Schneider Y., Chabert P., Stutzmann J., Coelho D., Fougerousse A., Gosse F., et al. Resveratrol analog (Z)-3,5,4'-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int J Cancer 2003, 107(2):189-196.
40. Colin D., Gimazane A., Lizard G., Izard J.C., Solary E., Latruffe N., et al. Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells. Int J Cancer 2009, 124(12):2780-2788.
41. Vidavalur R., Otani H., Singal P.K., Maulik N. Significance ofwine and resveratrol in cardiovascular disease: Frenchparadox revisited. Exp Clin Cardiol 2006, 11(3):217-225.
42. Adachi S., Nagao T., To S., Joe A.K., Shimizu M., Matsushima-Nishiwaki R., et al. (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. Carcinogenesis 2008, 29(10):1986-1993.
43. Shimizu M., Shirakami Y., Sakai H., Adachi S., Hata K., Hirose Y., et al. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev Res (Phila Pa) 2008, 1(4):298-304.
44. Aranganathan S., Panneer Selvam J., Nalini N. Hesperetin exerts dose dependent chemopreventive effect against 1,2-dimethyl hydrazine induced rat colon carcinogenesis. Invest New Drugs 2009, 27(3):203-213.
45. Nam K.S., Kim M.K., Shon Y.H. Chemopreventive effect of chitosan oligosaccharide against colon carcinogenesis. J Microbiol Biotechnol 2007, 17(9):1546-1549.
46. Lin S.Y., Chan H.Y., Shen F.H., Chen M.H., Wang Y.J., Yu C.K. Chitosan prevents the development of AOM-induced aberrant crypt foci in mice and suppressed the proliferation of AGS cells by inhibiting DNA synthesis. J Cell Biochem 2007, 100(6):1573-1580.
47. Holt P.R., Arber N., Halmos B., Forde K., Kissileff H., McGlynn K.A., et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 2002, 11(1):113-119.
48. Murillo G., Matusiak D., Benya R.V., Mehta R.G. Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer. J Steroid Biochem Mol Biol 2007, 103(3-5):763-767.
49. Johnson S.M., Gulhati P., Arrieta I., Wang X., Uchida T., Gao T., et al. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res 2009, 29(8):3185-3190.
50. Kunnumakkara A.B., Diagaradjane P., Anand P., Harikumar K.B., Deorukhkar A., Gelovani J., et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 2009, 125(9):2187-2197.
51. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52(9):1766-1777.
52. Mimura J. [Biological role of AhR signaling pathway]. Seikagaku 2004, 76(4):359-363.
53. Bass S.E., Sienkiewicz P., Macdonald C.J., Cheng R.Y., Sparatore A., Del Soldato P., et al. Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells. Clin Cancer Res 2009, 15(6):1964-1972.
54. Han A., Song Z., Tong C., Hu D., Bi X., Augenlicht L.H., et al. Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol 2008, 583(1):26-31.
55. Flis S., Splwinski J. Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide. Anticancer Res 2009, 29(1):435-441.
56. Cruz-Correa M., Hylind L.M., Romans K.E., Booker S.V., Giardiello F.M. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002, 122(3):641-645.
57. Giardiello F.M., Yang V.W., Hylind L.M., Krush A.J., Petersen G.M., Trimbath J.D., et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002, 346(14):1054-1059.
58. Meyskens F.L., McLaren C.E., Pelot D., Fujikawa-Brooks S., Carpenter P.M., Hawk E., et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa) 2008, 1(1):32-38.
59. van Stolk R., Stoner G., Hayton W.L., Chan K., DeYoung B., Kresty L., et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 2000, 6(1):78-89.
60. Zhu B., Vemavarapu L., Thompson W.J., Strada S.J. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 2005, 94(2):336-350.
61. Doherty G.A., Byrne S.M., Molloy E.S., Malhotra V., Austin S.C., Kay E.W., et al. Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. BMC Cancer 2009, 9:207.
62. Zhang H., Ye Y., Bai Z., Wang S. The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway. Dig Dis Sci 2008, 53(8):2195-2203.
63. Grosch S., Maier T.J., Schiffmann S., Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006, 98(11):736-747.
64. Yan M., Myung S.J., Fink S.P., Lawrence E., Lutterbaugh J., Yang P., et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A 2009, 106(23):9409-9413.
65. Cole B.F., Logan R.F., Halabi S., Benamouzig R., Sandler R.S., Grainge M.J., et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009, 101(4):256-266.
66. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Breazna A., Kim K., et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 2009, 2(4):310-321.
67. Baron J.A., Sandler R.S., Bresalier R.S., Quan H., Riddell R., Lanas A., et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131(6):1674-1682.
68. Rostom A.D.C., Lewin G., Dube C., Lewin G., Tsertsvadze A., Barrowman N., Code C., et al. (1)Routine aspirin or nonsteroidal anti-inflammatory drugs for the prevention of colorectal cancer: U.S. preventive services task force recommendation statement. (2)The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. (3)Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive task force. Ann Intern Med 2007, 146:361-375.
69. Swamy M.V., Patlolla J.M., Steele V.E., Kopelovich L., Reddy B.S., Rao C.V. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006, 66(14):7370-7377.
70. Din F.V., Theodoratou E., Farrington S.M., Tenesa A., Barnetson R.A., Cetnarskyj R., et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010, 59(12):1670-1679.